Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SN 38 loaded biodegradable nanofiber - Cebiotex

Drug Profile

SN 38 loaded biodegradable nanofiber - Cebiotex

Alternative Names: CEB-01; CEB-01 PLGA Membrane - Cebiotex

Latest Information Update: 14 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polytechnic University of Catalonia; The Sant Joan de Deu Hospital in Barcelona
  • Developer Cebiotex
  • Class Antineoplastics; Camptothecins; Indolizines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Soft tissue sarcoma

Most Recent Events

  • 14 Dec 2023 Phase-I development in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in Spain (NCT04619056)
  • 20 Oct 2023 Adverse events and pharmacokinetics data from a phase I trial in Soft tissue sarcoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top